ABSTRACT
Objective:To explore pathological features and survival of triple positive breast cancer (TPBC).Methods:The clinical data of 271 cases of triple positive breast cancer from January 2010 to January 2017 in Suqian area were collected,compared with 283 cases of Luminal B I (HER2 negative).The clinical pathological features and survival were analyzed.Results:Among 271 cases of triple positive breast cancer,there were 89 cases (32.84％) of distant recurrence and metastasis in 2 years,and 137 cases (50.55％) of distant recurrence in 5 years.Among 283 cases of Luminal B I,there were 32 cases (11.31 ％) of distant recurrence and metastasis in 2 years.and 52 cases (18.37％) of distant recurrence in 5 years.There were significantly differences(P＜0.05).1 year Disease-free survival (DFS)and Overall survival (OS) of all patients were 100％,Among 271 cases of triple positive breast cancer,2-year DFS and OS were 64.94 ％,85.24％ respectively.3-year DFS and OS were 54.98 ％,69.74％ respectively,5-year DFS and OS were 43.54％,47.23％ respectively.Among 283 cases of Luminal B I,2-year DFS and OS were 86.22 ％,95.76％ respectively.3-year DFS and OS were 81.98 ％,80.92％ respectively,5-year DFS and OS were 76.33％,67.49％ respectively.There were significantly differences(P＜0.05).Conclusion:TPBC has the characteristics of poor biological behavior,large mass,pathological grade of grade Ⅲ,vascular or nerve infiltration,axillary lymph node metastasis,high proliferation index and high tumor load,and early distant recurrence,low DFS and OS.We Should choose individualized,targeted treatment programs,based on patient's hormone receptor and Ki67 expression,so as to benefit patients of TPBC.
ABSTRACT
Objective To investigate the expression and clinical significance of plasma microRNA 10b (miRNA-10b) in patients with cervical cancer.Methods The levels of plasma miRNA-10b,SCCA and CEA were detected by RT-PCR in 168 patients with cervical cancer,68 patients with CIN (CIN group) and 45 healthy women (control group),analyzed the relation between miRNA 10b expression and clinicopathological features of cervical cancer.The sensitivity and specificity of miRNA-10b,SCCA and CEA in the diagnosis of cervical cancer were evaluated by ROC curve,and the relationship between three indexes and cervical cancer were analyzed by multivariate Logistic regression model.Correlation analysis of plasma miRNA-10b and SCCA,CEA in patients with cervical cancer was analysed by Pearson.Results The levels of miRNA-10b,SCCA and CEA in the cervical cancer group were significantly higher than those in the CIN group and the control group[miRNA-10b(2-△△Ct):5.83± 1.84 vs 2.64±0.92 and 2.38±0.75;SCCA(ng/ml):8.74±2.26 vs 1.97±0.62 and 0.61±0.15;CEA (ng/ml):5.71±2.15 vs 1.56±0.58 and 1.34±0.16,F=17.842,13.614,8.273,all P＜0.01].The level of plasma miRNA-10b expression was correlated with clinical stage,lymph node metastasis,depth of invasion and SCCA level in patients with cervical cancer(t/F=19.287,21.528,5.672,5.284,P＜0.05).Plasma miRNA-10b,SCCA and CEA and three combined diagnosis of cervical cancer of AUC (95％CI) were 0.836(0.752～0.924),0.795(0.722～0.875),0.664(0.596～0.738) and 0.882(0.794～0.958),respectively.The optimal cut-off values were 4.26,6.58 ng/ml and 4.05 ng/ml,respectively.Logistic regression analysis showed that elevated plasma miRNA-10b and SCCA levels were independent risk factors for cervical cancer[OR(95％CI)=1.816(1.629～2.483),OR(95％CI) =1.427(1.206～ 1.975)].Plasma miRNA-10b was positively correlated with SCCA in patients with cervical cancer(r=0.637,P＜0.01).Conclusion Plasma miRNA-10b will be expected to be a molecular marker for the early diagnosis of cervical cancer.The combination of SCCA and CEA can improve the diagnostic accuracy of cervical cancer.
ABSTRACT
<p><b>OBJECTIVE</b>Neonatal hypoxic-ischemic encephalopathy (HIE) harms the lives and health of newborn infants and children severely. The prognosis is not satisfied, especially of the severe HIE. Mesenchymal stem cells (MSCs) can secrete a series of growth factors and neurotrophic factors. As well they have the potential ability to differentiate to the neural cells in vitro and in vivo. Therefore MSCs transplantation has been employed as a source of progenitor cells for cell therapy in patients with HIE in order to promote recovery of brain function and reduce the sequelae. Studies have shown that MSCs could enter the cerebral parenchyma and differentiate to neural cells through systemic infusion, but most of the researches applied adult stroke animal models. This study used neonatal HIE models to test the hypothesis that MSCs could enter the brain of newborn Wistar rats through the blood-brain barrier (BBB) by intraperitoneal infusion followed by observing the characteristics of the distribution and differentiation of MSCs in brain tissues, and exploring the effects of hypoxic-ischemic brain damage to the penetration and differentiation of MSCs.</p><p><b>METHODS</b>Isolation and purification of MSCs were established from the whole bone marrow of juvenile Wistar rats by removing the nonadherent cells in primary and passage cultures. For cellular identification, MSCs of three to five passages were continuously pre-labeled with 5-bromo-2-deoxyuridine (BrdU) for 72 hours before transplantation. Animal models of HIE were built in 7-day-postnatal Wistar rats according to the method described by Rice. Two hours after hypoxia-ischemia, rats in HIE group (n = 8) were intraperitoneally infused with MSCs (4 x 10(6), 0.5 ml). In control group (n = 8), 7-day-postnatal normal Wistar rats were intraperitoneally infused with the same amount of MSCs. All rats were sacrificed and their cerebra were sectioned by cryomicrotome 14 days after transplantation. Immunohistochemical staining with chromogen diaminobenzidine (DAB) was used to detect and measure the cells derived from MSCs, and study the characteristics of distribution. To determine the differentiation of the BrdU positive cells entering the brains, immunofluorescence double labeling for BrdU and neural cells specific antigens was performed.</p><p><b>RESULTS</b>MSCs were distributed throughout the cerebra in both groups at the 14th day after transplantation. The number of MSCs detected was 2415 +/- 226 in the control group, and 3626 +/- 461 in HIE group, respectively (t = 6.68, P < 0.05). More BrdU reactive cells were observed in the right ischemic hemisphere (1904 +/- 267) than in the contralateral hemisphere (1723 +/- 204), (t = 4.47, P < 0.05). No significant difference was found while comparing both cerebral hemispheres of the control group (t = 0.31, P > 0.05). In the HIE group, MSCs distributed more extensively, and some focal aggregations of MSCs were noticed. A few MSCs expressed Nestin-protein marker of neural progenitor cells, and almost none of the MSCs which expressed proteins characteristic of neuron (e.g. NSE) and astrocyte (e.g. GFAP) was detected at the 14th day after transplantation.</p><p><b>CONCLUSION</b>1. MSCs could enter the cerebral parenchyma through BBB and migrate throughout the brain by intraperitoneal infusion. 2. More MSCs injected intraperitoneally were localized and directed to the sites of hypoxic-ischemic brain damage. 3. Transplanted MSCs could not differentiate to neuron and astrocyte without other interventions during 14 days after transplantation.</p>